306 related articles for article (PubMed ID: 27282576)
1. Assessment of serum bioactive hepcidin-25, soluble transferrin receptor and their ratio in predialysis patients: Correlation with the response to intravenous ferric carboxymaltose.
Drakou A; Margeli A; Theodorakopoulou S; Agrogiannis I; Poziopoulos C; Papassotiriou I; Vlahakos DV
Blood Cells Mol Dis; 2016 Jul; 59():100-5. PubMed ID: 27282576
[TBL] [Abstract][Full Text] [Related]
2. Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial.
Gaillard CA; Bock AH; Carrera F; Eckardt KU; Van Wyck DB; Bansal SS; Cronin M; Meier Y; Larroque S; Roger SD; Macdougall IC
PLoS One; 2016; 11(6):e0157063. PubMed ID: 27276035
[TBL] [Abstract][Full Text] [Related]
3. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
[TBL] [Abstract][Full Text] [Related]
4. Hepcidin and diabetes are independently related with soluble transferrin receptor levels in chronic dialysis patients.
Belo L; Rocha S; Valente MJ; Coimbra S; Catarino C; Bronze-da-Rocha E; Rocha-Pereira P; do Sameiro-Faria M; Oliveira JG; Madureira J; Fernandes JC; Miranda V; Santos-Silva A
Ren Fail; 2019 Nov; 41(1):662-672. PubMed ID: 31296086
[No Abstract] [Full Text] [Related]
5. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
Toblli JE; Di Gennaro F
PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
[TBL] [Abstract][Full Text] [Related]
6. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
Charytan C; Bernardo MV; Koch TA; Butcher A; Morris D; Bregman DB
Nephrol Dial Transplant; 2013 Apr; 28(4):953-64. PubMed ID: 23222534
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea.
Jang JH; Kim Y; Park S; Kim K; Kim SJ; Kim WS; Jung CW; Lee J; Lee SH
PLoS Med; 2020 Jun; 17(6):e1003091. PubMed ID: 32511251
[TBL] [Abstract][Full Text] [Related]
8. Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial.
Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Meier Y; Larroque S; Roger SD;
BMC Nephrol; 2017 Jan; 18(1):24. PubMed ID: 28095881
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing.
Diebold M; Kistler AD
BMC Nephrol; 2019 Mar; 20(1):76. PubMed ID: 30823916
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and tolerability of ferric carboxymaltose in geriatric patients with anemia. Data from three non-interventional studies].
Röhrig G; Steinmetz T; Stein J; Geisel T; Virgin G; Schaefer R; Bach M; Schulz RJ
MMW Fortschr Med; 2014 Jul; 156 Suppl 2():48-53. PubMed ID: 25351027
[TBL] [Abstract][Full Text] [Related]
11. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Nolen JG; Roger SD;
Nephrol Dial Transplant; 2014 Nov; 29(11):2075-84. PubMed ID: 24891437
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of reticulocyte hemoglobin content, percentage of hypochromic red blood cells, and ratio of serum transferrin receptor level/serum iron level as markers of iron-deficiency erythropoiesis in patients undergoing hemodialysis].
Hasegawa M; Kawamura N; Koide S; Murase M; Asano S; Toba T; Kushimoto H; Murakami K; Tomita M; Hasegawa H; Shikano M; Mizuno M; Funahashi N; Kawashima S; Sugiyama S
Nihon Jinzo Gakkai Shi; 2002; 44(5):453-63. PubMed ID: 12216478
[TBL] [Abstract][Full Text] [Related]
13. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
[TBL] [Abstract][Full Text] [Related]
14. [Assessment of iron deficiency anemia management in the general hospital of Grenoble: A 12-month follow-up of an intravenous ferric carboxymaltose treatment program in a cohort of patients with non-dialysis-dependent chronic kidney disease].
Romanet T; Bedouch P; Zaoui P
Nephrol Ther; 2019 Apr; 15(2):104-109. PubMed ID: 30803900
[TBL] [Abstract][Full Text] [Related]
15. The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale.
Macdougall IC; Bock A; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Cushway T; Roger SD;
Nephrol Dial Transplant; 2014 Apr; 29(4):843-50. PubMed ID: 24170814
[TBL] [Abstract][Full Text] [Related]
16. [Iron deficiency in ND-CKD: from diagnosis to treatment].
Liberti ME; Garofalo C; Sagliocca A; Borrelli S; Conte G; De Nicola L; Minutolo R
G Ital Nefrol; 2017 Sep; 34(5):50-61. PubMed ID: 28963827
[TBL] [Abstract][Full Text] [Related]
17. Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study.
Viethen T; Gerhardt F; Dumitrescu D; Knoop-Busch S; ten Freyhaus H; Rudolph TK; Baldus S; Rosenkranz S
Int J Cardiol; 2014 Aug; 175(2):233-9. PubMed ID: 24880481
[TBL] [Abstract][Full Text] [Related]
18. Use of intravenous iron supplementation in chronic kidney disease: an update.
Macdougall IC; Geisser P
Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
[TBL] [Abstract][Full Text] [Related]
19. Erythropoiesis-driven regulation of hepcidin in human red cell disorders is better reflected through concentrations of soluble transferrin receptor rather than growth differentiation factor 15.
Fertrin KY; Lanaro C; Franco-Penteado CF; de Albuquerque DM; de Mello MR; Pallis FR; Bezerra MA; Hatzlhofer BL; Olbina G; Saad ST; da Silva Araújo A; Westerman M; Costa FF
Am J Hematol; 2014 Apr; 89(4):385-90. PubMed ID: 24860871
[TBL] [Abstract][Full Text] [Related]
20. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia.
Bregman DB; Morris D; Koch TA; He A; Goodnough LT
Am J Hematol; 2013 Feb; 88(2):97-101. PubMed ID: 23335357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
